Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

| PRESCRIBER | | PATIENT: | | |
|--|---|-------------|--|--|
| Name | | Name: | | |
| Ward: | | NHI: | | |
| Siltu | ximab | | | |
| Re-a | ATION seesessment required after 6 months equisites (tick boxes where appropriate) Prescribed by, or recommended by a haematologist or rheumatologist the Health NZ Hospital. Patient has severe HHV-8 negative idiopathic multicentric Cas and Treatment with an adequate trial of corticosteroids has proven and Siltuximab is to be administered at doses no greater than 11 m | ineffective | | |
| CONTINUATION Re-assessment required after 12 months Prerequisites (tick box where appropriate) Or Prescribed by, or recommended by a haematologist or rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital. and The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status | | | | |

I confirm that the above details are correct:

| 0: | D - 1 - 1 | |
|-----------|-----------|--|
| Zigneg. | i jate: | |
| Oigilica. | Duic. | |